All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Oncology Drugs in Phase III Clinical Development in FINLAND

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Orion Corporation

Virtual Booth Begin the journey of your innovative API with Fermion.

FINLAND Finland

Contact Supplier

ASCO 2020

Participation Not Confirmed

Update your events

ARAMIS Phase III Data to be Presented At ASCO 2020 Reveals Nubeqa Linked with Improved Overall Survival In Non-Metastatic Prostate Cancer

Contact the Supplier

Lead Product(s): Darolutamide

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Darolutamide significantly reduced risk of death by 31 percent in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

Orion Corporation

Virtual Booth Begin the journey of your innovative API with Fermion.

FINLAND Finland

Contact Supplier

ASCO 2020

Participation Not Confirmed

Update your events

Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer

Contact the Supplier

Lead Product(s): Darolutamide

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

The CHMP recommendation is based on the results of the Phase III ARAMIS trial evaluating darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT.